Secukinumab

Secukinumab
	Autoinjector with Cosentyx by Novartis (secukinumab)
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL17A
Clinical data
Trade names	Cosentyx
Other names	AIN457
AHFS/Drugs.com	Monograph
MedlinePlus	a615011
License data	US DailyMed: Secukinumab;
Pregnancy; category	AU: C;
Routes of; administration	Subcutaneous, intravenous
ATC code	L04AC10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	875356-43-7 (heavy chain); 875356-44-8 (light chain);
DrugBank	DB09029 ;
ChemSpider	none;
UNII	DLG4EML025;
KEGG	D09967;
Chemical and physical data
Formula	C6584H10134N1754O2042S44
Molar mass	147944.37 g·mol−1
	(what is this?) (verify)

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.